Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan
JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc (NASDAQ:VKTX) with an Overweight rating and a ...
BioWorld1mon
LTZ raises $20M to bring LTZ-301 to clinic for B-cell tumors
Immunotherapy-focused biotech company LTZ Therapetics Inc. raised $20 million in a series A round that will advance development of its myeloid engager pipeline to treat cancer and autoimmune diseases.
Buy Rating Affirmed for Viking Therapeutics as VK2735 Shows Promising Weight Loss and Safety Profile
In a report released today, Michael Ulz from Morgan Stanley reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), with ...
BioWorld13d
Series A
Candid Therapeutics Inc. launched with ex-China control of two bispecific T-cell engager antibodies that it plans to develop for autoimmune diseases. The San Diego-based company will start off with a ...